CGT · 다발성 골수종 | 바이오모아

CGTBiologicThomas Martin, MDPhase 1

Biospecimen Collection (Biospecimen Collection)

Multiple Myeloma; Recurrent Multiple Myeloma · FRα

#FR#CGT#Phase1#인기#세포유전치료+5

효능 ORR 11.11%임상시험 61상태 DISCONTINUED

CGTBiologicSung-Soo ParkPreclinical

IMiD treatment (IMiD treatment)

Multiple Myeloma, Relapsed; Multiple Myeloma (MM) · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5

효능 ORR 48.3%임상시험 39상태 RECRUITING

CGTBiologicYake Biotechnology Ltd.Phase 1

APRIL CAR-T cells (APRIL CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5

임상시험 4상태 RECRUITING

CGTBiologicM.D. Anderson Cancer Centervedotin (BV) and, in Hodgki…Phase 2

Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells (Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells)

Relapsed/Refractory Myeloma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 1상태 RECRUITING

CGTBiologicstaleLuminary TherapeuticsPhase 1

Autologous CAR-T cell therapy expressing the BAFF-ligand. (Autologous CAR-T cell therapy expressing the BAFF-ligand.)

Multiple Myeloma, Refractory; Multiple Myeloma in Relapse · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5

임상시험 1상태 RECRUITING

CGTBiologicstaleShanghai Changzheng HospitalPhase 1

CAR-T cells Infusion (CAR-T cells Infusion)

Relapsed/Refractory Multiple Myeloma; Relapsed/Refractory Plasma Cell Leukemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

효능 ORR 67%임상시험 1상태 RECRUITING

CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Phase 1

CAR-T cells Infusion chimeric antigen receptor T cells (CAR-T cells Infusion chimeric antigen receptor T cells)

Relapsed/Refractory Plasma Cell Leukemia; Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Preclinical

CT0590 CAR T Cells (CT0590 CAR T Cells)

Relapsed and/or Refractory Multiple Myeloma · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+4

임상시험 1상태 ACTIVE

CGTBiologicstaleMedical College of WisconsinPhase 1

1 x 10^8 cells per dose (FT836 CAR T cells, FT836 CAR T cells (1 x 10^8 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleMedical College of WisconsinPhase 1

3 x 108 cells per dose (FT836 CAR T cells, FT836 CAR T cells (3 x 108 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleMedical College of WisconsinPhase 1

up to 9 x 108 cells per dose (FT836 CAR T cells, FT836 CAR T cells (up to 9 x 108 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleThe First Hospital of Jilin Uni…Phase 2

IL-15-armored CAR-T cells (IL-15-armored CAR-T cells)

Relapsed/Refractory Multiple Myeloma; Plasma Cell Leukemia (PCL) · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5

효능 ORR 50%임상시험 1상태 RECRUITING

CGTBiologicstaleNanjing Legend Biotech Co.Phase 1

LCAR-B4822M CAR-T Cell Immunotherapy (LCAR-B4822M CAR-T Cell Immunotherapy)

Refractory or Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

CGTBiologicstaleMemorial Sloan Kettering Cancer…Phase 1

MCARH109 (MCARH109)

Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleMemorial Sloan Kettering Cancer…Phase 1

MCARH125 (MCARH125)

Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleHadassah Medical OrganizationPhase 1

Naive HBI0101 CAR-T (Naive HBI0101 CAR-T)

Relapsed/Refractory Multiple Myeloma (MM) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstalePrecision BioSciences, Inc.Phase 1

PBCAR269A (PBCAR269A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 DISCONTINUED

CGTBiologicstaleCellectis S.A.Phase 1

UCARTCS1A (UCARTCS1A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 DISCONTINUED

갱신 기록 없음 · 14일 주기 · 방문 16 / 568